EU/3/18/2032: Orphan designation for the treatment in haematopoietic stem cell transplantation

carmustine

Overview

On 27 June 2018, orphan designation (EU/3/18/2032) was granted by the European Commission to Adienne S.r.l. S.U., Italy, for carmustine for treatment in haematopoietic stem cell transplantation.

Key facts

Active substance
carmustine
Intented use
Treatment in haematopoietic stem cell transplantation
Orphan designation status
Positive
EU designation number
EU/3/18/2032
Date of designation
27/06/2018
Sponsor
ADIENNE S.r.l.S.U.
Via Galileo Galilei, 19
20867 Caponago (MB)
Italy
Tel: +39 02 40 70 04 45
E-mail: adienne@adienne.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating